컴퓨젠(CGEN) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

CGEN

Compugen Ltd

7월 27일 4:00 PM ET (한국 7/28 05:00)

$2.38

+0.10 ▲ +4.39%

🌙 7월 27일 7:45 PM ET (한국 7/28 08:45)

$2.40

+0.02 ▲ +0.63%

컴퓨젠(CGEN) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$225M

스몰캡

P/E

6.5

저평가 구간

배당수익률

없음

52주 위치

56%

저점 +84% · 고점 -26%

애널리스트

적극 매수

C+

Fundamental health

vs. Biotechnology 초소형주

수익성

Top 4%

성장

Top 65%

밸류에이션

Top 62%

재무 안정

Top 52%

Index ⓘ	-	P/E ⓘ	6.5	EPS (ttm) ⓘ	0.37	Insider Own ⓘ	2.19%	Shs Outstand ⓘ	94.5M	Perf Week ⓘ	1.71%
Market Cap ⓘ	0.23B	Forward P/E ⓘ	-	EPS next Y ⓘ	1.75%	Insider Trans ⓘ	-2.26%	Shs Float ⓘ	92.5M	Perf Month ⓘ	17.82%
Enterprise Value ⓘ	0.09B	PEG ⓘ	-	EPS next Q ⓘ	-0.08	Inst Own ⓘ	15.27%	Short Float ⓘ	3.27%	Perf Quarter ⓘ	-23.23%
Income ⓘ	0.03B	P/S ⓘ	3.1	EPS this Y ⓘ	-176.54%	Inst Trans ⓘ	1.85%	Short Ratio ⓘ	7.09	Perf Half Y ⓘ	13.88%
Sales ⓘ	0.07B	P/B ⓘ	2.36	EPS next 5Y ⓘ	-	ROA ⓘ	26.68%	Short Interest ⓘ	3.03M	Perf YTD ⓘ	55.56%
Book/sh ⓘ	1.01	P/C ⓘ	1.67	EPS past 3/5Y ⓘ	-	ROE ⓘ	45.72%	52W High ⓘ	-26.43% ($3.23)	Perf Year ⓘ	55.56%
Cash/sh ⓘ	1.43	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	113.28% 105.2%	ROIC ⓘ	35.67%	52W Low ⓘ	83.78% ($1.29)	Perf 3Y ⓘ	131.07%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	336.89%	Gross Margin ⓘ	88.06%	Volatility(W/M) ⓘ	4.81% 4.53%	Perf 5Y ⓘ	-62.7%
Dividend TTM ⓘ	-	EV/Sales ⓘ	1.28	Sales Y/Y TTM ⓘ	163.35%	Oper. Margin ⓘ	42.26%	ATR (14) ⓘ	0.11	Perf 10Y ⓘ	-64.74%
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	6.23	EPS Q/Q ⓘ	-4.24%	Profit Margin ⓘ	47.97%	RSI (14) ⓘ	53.6	Recom ⓘ	1
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	6.23	Sales Q/Q ⓘ	-4.73%	SMA20 ⓘ	2.06% ($2.33)	Beta ⓘ	2.77	Target Price ⓘ	$4.6
Payout ⓘ	-	Debt/Eq ⓘ	0.03	Earnings ⓘ	2026/8/3	SMA50 ⓘ	2.12% ($2.33)	Rel Volume ⓘ	0.24	Prev Close ⓘ	$2.28
Employees ⓘ	75	LT Debt/Eq ⓘ	0.02	EPS/Sales Surpr. ⓘ	-14.29% 38.47%	SMA200 ⓘ	15.02% ($2.07)	Avg Volume(3M) ⓘ	0.43M	Price ⓘ	$2.38
IPO ⓘ	2000/8/11	Option/Short ⓘ	Yes/Yes			Trades ⓘ	1125	Volume ⓘ	103,539	Change ⓘ	4.39%

Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Compugen Ltd (CGEN) Investment Analysis

What kind of company is Compugen Ltd?

컴퓨젠(CGEN) 초고성장주

Healthcare · Biotechnology

Small-Cap — Low Volume, High Volatility

🧬 Compugen is an Israel-based biotech that uses its proprietary computational platform for novel drug discovery to identify immuno-oncology targets. The company focuses on the early-stage discovery of next-generation immune checkpoint targets and runs both in-house clinical development and global pharma licensing in parallel, operating a pipeline of therapeutic candidates for solid tumors.

Learn more about Compugen Ltd →

Market Cap

$0.2B

Approx. KRW 0.3 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank3999

Employees75people

IPO2000/08/11

Current Price$2.38 ≈ 3,261원

NASD · Israel

Key Events

⏰ Upcoming events

🔔 Earnings release D-6

8월 3일 (월) · 장 시작 전

예상 매출 - · EPS $-0.09

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 18일 (월) · 장 시작 전 EPS -14.3% 매출 +38.5%

🔔 Earnings release 2026년 3월 2일 (월) · 장 시작 전 EPS +900.0% 매출 +3018.2%

Is it profitable?

Solid company — profitability & finances both healthy

Strong earnings and excellent financial health

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

42.3%

✓ 우수

My positionTop 5%

Low range Average High range

Biotechnology 초소형주 Median -778.0% · Top tier

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

48.0%

✓ 우수

My positionTop 5%

Low range Average High range

Biotechnology 초소형주 Median -911.1% · Top tier

💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

88.1%

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology 초소형주 Median 53.4% · Top 23%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

45.7%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 초소형주 Median -98.0% · Top tier

💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)

ROA

Annual earnings relative to total company assets

26.7%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 초소형주 Median -59.3% · Top tier

💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수

ROIC

Return generated per dollar invested in the business

35.7%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 초소형주 Median -77.3% · Top tier

💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.03

✓ Healthy debt

My positionMid-range

Low range Average High range

Biotechnology Median 0.05

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

6.23

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

6.23

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$4.60

현재가 대비 +93.3%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

내년 EPS 예상 성장률

+1.8%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance

Slight tendency to beat estimates

예상 상회

예상 부합

예상 하회

50%

상회 비율

+169.5%

평균 서프라이즈

2026.05.18

부합

실적 $-0.08 · 예상 $-0.08 +0.0%

2026.03.02

상회

실적 $0.60 · 예상 $0.14 +339.0%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Growth Expected to Slow

Historical growth is expected to lose momentum

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

-176.5%

매우 부진

My positionBottom 5%

Low range Average High range

초고성장주 초소형주 Median 50.1% · Bottom tier

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+1.8%

부진

My positionBottom 25%

Low range Average High range

초고성장주 초소형주 Median 35.0% · Bottom 14%

📊 How much has it grown? (actual results)

Past 5-Year Revenue

How much revenue grew over the past 5 years

+105.2%

우수

My positionTop 25%

Low range Average High range

초고성장주 초소형주 Median 47.0% · Top 17%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

-4.7%

평균

My positionMid-range

Low range Average High range

초고성장주 초소형주 Median 3.6% · Bottom 44%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -131%p below the market

CGEN -62.7% · S&P 500 +68.4%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-131.1%p

Significantly behind the market

vs Health Care (XLV)

-87.2%p

Significantly behind the sector average

1-year basis

vs S&P 500

+39.5%p

well ahead of the market

vs Health Care (XLV)

+35.8%p

well ahead of the sector average

Rank among peers

5-year return Top among peers Based on 245 peers

1-year return Top 13% Based on 315 peers

Current position within 52-week range

Low (-83.8%p) High (-26.4%p)

Current price is 83.8% above the 52-week low and 26.4% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-36.8%

Annualized volatility

67.6%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢

Current diagnosis · 2026-07-27

Uptrend zone

Current price $2.38 above the midline ($2.33). Normal upward flow. Inside the Ichimoku cloud (neutral).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟢

Current diagnosis · 2026-07-27

Bullish momentum holding

MACD 0.029 > Signal 0.024 in positive zone + Hist positive (+0.005). Trend in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢

Current diagnosis · 2026-07-27

Bullish zone

RSI 53.5 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 47.1.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry

Cheap on Vs. Earnings·Vs. Sales, In line with peers on Vs. Assets

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Cheap

🏢 Vs. Assets Mid-range

🧾 Vs. Sales Cheap

💵 Vs. Earnings

PER Price-to-Earnings Ratio

How expensive the price is vs. earnings — lower is cheaper

6.50x

✓ Cheap

My positionMid-range

Low range Average High range

Biotechnology median 15.34x · Around the industry average

💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

2.36x

✓ Fair

My positionMid-range

Low range Average High range

Biotechnology 초소형주 median 1.35x · Around the industry average

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

3.10x

✓ Very cheap

My positionTop 25%

Low range Average High range

Biotechnology 초소형주 median 11.24x · Top 24% — relatively cheap within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

Analyst target price (reference)

$4.60 vs. current price +93.3%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology

Who owns it?

Ownership flow is positive

Insider modest net selling -2.3% · Institutional net buying +1.9% · Short interest light 3.3% · Short interest up +2.1pp over last 90d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

-2.3%

Insiders net selling

🏦 Institutions (funds & investors)

+1.9%

Institutions net buying

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 15.3%

Retail-led

Healthcare 초소형주 Median 14.2%

🧑‍💼 Insiders 2.2%

Typical level

Healthcare 초소형주 Median 16.1%

👤 Retail investors (estimated) 82.5%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

3.3%

Low — limited short-side pressure

Healthcare 초소형주 Median 3.9%

Past 90 days 📈 +2.1%p increase

Short interest days to cover

7.1 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 94.5M주

Float (tradable shares) 92.5M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding CGEN

ETFs with the highest weightings · 3 total shown

IZRL

ARK Israel Innovative Technology ETF

1.47%

$139M

GWX

State Street SPDR S&P International Small Cap ETF

0.02%

$857M

SPDW

State Street SPDR Portfolio Developed World ex-US ETF

0.00%

$39.7B

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
CGEN This Stock	$225.0M	6.5 ▲	2.4 ▲	45.72% ▲	-	+4.4%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 컴퓨젠(CGEN)?

컴퓨젠(CGEN) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of CGEN?

The market cap of CGEN is approximately $225M, ranking 3,999 within its sector.

What is the P/E ratio of CGEN?

CGEN has a P/E ratio of approximately 6.5x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for CGEN?

CGEN has recorded a 52-week high of $3.23 and a low of $1.29.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.